PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Emerging Markets
What Can Big Pharma Learn From Other Industries in Emerging Markets?
Building a durable base for growth in emerging markets is top line in pharma’s strategy to compensate for slowing sales in the US and Europe. Key to success is moving beyond the traditional reliance on serving the smallest, most affluent segment of the market to seed critical mass: expanding resources for health, broadening the customer [...]
Posted in Emerging Markets, IP, Market Access, Marketing, Strategy Also tagged Market Access 1 Comment
Drug Payment Reform in China: Now That's a Mass Market
The task of building drug access for one billion new customers in China is probably this decade’s grandest public policy experiment. It is taking place largely behind the scene in a series of often tense exchanges between Beijing and local governments – the dialogue is worth watching for the long-term commercial implications in what all [...]
Posted in Emerging Markets, Global, Strategy Also tagged China, payment reform, Regulatory Leave a comment
Emerging Countries Closing in on Western R&D
UNESCO report reveals seismic shift in the world’s R&D balance.
The US, Europe, and Japan may still be leading the global R&D effort, but emerging countries, especially China, are hot on their heels, says a UNESCO report launched yesterday (World Science Day). While investment in R&D is growing globally in volume, the emerging countries are rapidly [...]
Report Reveals Global Supply Chain Fears
A new report published by Axendia is calling for better collaboration with suppliers, distributors, shippers, and regulators.
Global pharmaceutical outsourcing has become increasingly prevalent, but is creating a complex and risky supply chain environment that has pharmaceutical and life sciences executives on high alert, according to a new study co-sponsored by PwC and published last [...]
Posted in Biotech, Emerging Markets, Global, Supply Chain Also tagged globalization, outsourcing, Supply Chain, visibility Leave a comment
New Decade, New Agenda for Pharma